What is the effect of radioiodine therapy on Helicobacter pylori infection?

Amaç & Hipotez:Helicobacter pylori is an important human pathogen associated with gastric and duodenal ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and adenocarcinoma.

📊

Temel Bulgular & Veri:Of those, 76 patients had differentiated thyroid cancer and 11 had primary hyperthyroidism.

💡

Sonuç & Katkı:Conclusion: RAI does not have any therapeutic effect on H. pylori infection.

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Key words: Helicobacter pylori · radioiodine therapy · differentiated thyroid cancer

Özet

Helicobacter pylori is an important human pathogen associated with gastric and duodenal ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and adenocarcinoma. Radioiodine (RAI) treatment plays an important role in the management of differentiated thyroid cancer and primary hyperthyroidism. It is known that during RAI treatment, a considerable amount is absorbed by the stomach as well. In this study we aimed to reveal any therapeutic impact of RAI on H. pylori infections. Materials and methods: Eighty-seven patients who were hospitalized for RAI treatment were consecutively included in this study. Of those, 76 patients had differentiated thyroid cancer and 11 had primary hyperthyroidism. The urea breath test (UBT) was performed on the day before RAI, and the test was repeated after 2 months. Results: The dose of RAI was 115 ± 3.3 mCi (range: 100–150 mCi) in the patients with malignant disease and 22.7 ± 1.4 mCi (range: 20–30 mCi) in the remaining patients. Among the patients with differentiated thyroid cancer, 44 (57%) had positive and 32 (43%) had negative UBT tests prior to RAI. Four (36%) patients with hyperthyroidism had pretreatment positive UBT tests and 7 (64%) had negative tests. The results of UBT conducted 2 months after RAI therapy were identical in every patient, which means that none of the patients with positive UBT became UBT-negative (P = 1). Conclusion: RAI does not have any therapeutic effect on H. pylori infection.

Abstract

Helicobacter pylori is an important human pathogen associated with gastric and duodenal ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and adenocarcinoma. Radioiodine (RAI) treatment plays an important role in the management of differentiated thyroid cancer and primary hyperthyroidism. It is known that during RAI treatment, a considerable amount is absorbed by the stomach as well. In this study we aimed to reveal any therapeutic impact of RAI on H. pylori infections. Materials and methods: Eighty-seven patients who were hospitalized for RAI treatment were consecutively included in this study. Of those, 76 patients had differentiated thyroid cancer and 11 had primary hyperthyroidism. The urea breath test (UBT) was performed on the day before RAI, and the test was repeated after 2 months. Results: The dose of RAI was 115 ± 3.3 mCi (range: 100–150 mCi) in the patients with malignant disease and 22.7 ± 1.4 mCi (range: 20–30 mCi) in the remaining patients. Among the patients with differentiated thyroid cancer, 44 (57%) had positive and 32 (43%) had negative UBT tests prior to RAI. Four (36%) patients with hyperthyroidism had pretreatment positive UBT tests and 7 (64%) had negative tests. The results of UBT conducted 2 months after RAI therapy were identical in every patient, which means that none of the patients with positive UBT became UBT-negative (P = 1). Conclusion: RAI does not have any therapeutic effect on H. pylori infection.

Anahtar kelimeler

Key words: Helicobacter pylori radioiodine therapy differentiated thyroid cancer urea breath test

🔖

Bu Makaleye Atıf Yap

USLUOĞULLARI, C. A., ÖNAL, E. D., ÖZDEMİR, E., CANER, S., ERSOY, O., ERSOY, R., ÇAKIR, B. (2014). What is the effect of radioiodine therapy on Helicobacter pylori infection?. Turkish Journal of Medical Sciences, Cilt: 44 - Sayı: 3, 520–523. https://ajindex.com/articles/258923

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19: 449–490.
Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175–1186.
Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134: 306– 3 Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007; 133: 985–1001.
Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89: 3668–3676.
Gurgul E, Sowinski J. Primary hyperthyroidism--diagnosis and treatment. Indications and contraindications for radioiodine therapy. Nucl Med Rev Cent East Eur 2011; 14: 29–32.
Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complimentary deoxyribonucleic acids from salivary gland, mammary gland and gastric mucosa. J Clin Endocrinol Metab 1998; 83: 1746–1751.
Shapiro B, Rufini V, Jarwan A, Geatti O, Kearfott KJ, Fig LM, Kirkwood ID, Gross MD. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med 2000; 30: 115–132.
Gholamrezanezhad A, Mirpour S, Saghari M, Abdollahzadeh J, Pourmoslemi A, Yarmand S. Radio-iodine therapy and Helicobacter pylori infection. Ann Nucl Med 2008; 22: 917–920.
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143– 11 Malfertheiner P, Megraud F, O’Morain C, Bell D, Bianchi Porro G, Deltenre M, Forman D, Gasbarrini G, Juap B, Misiewicz JJ et al. Current European concepts in the management of helicobacter pylori infection. The Maastricht consensus report. The European Helicobacter pylori study group (EHPSG). Eur J Gastroenterol Hepatol 1997; 9: 1–2. Mégraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374–1384.
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T et al. European Helicobacter Study Group. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–664.
Gisbert JP, Gonza